First Heartland Consultants Inc. Has $459,000 Holdings in Pfizer Inc. (NYSE:PFE)

First Heartland Consultants Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 2.9% in the third quarter, Holdings Channel.com reports. The firm owned 15,860 shares of the biopharmaceutical company’s stock after purchasing an additional 449 shares during the quarter. First Heartland Consultants Inc.’s holdings in Pfizer were worth $459,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Olistico Wealth LLC acquired a new position in Pfizer in the 2nd quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the 2nd quarter worth about $29,000. Quarry LP bought a new stake in Pfizer during the 2nd quarter worth about $31,000. Financial Connections Group Inc. bought a new stake in Pfizer during the 2nd quarter worth about $34,000. Finally, ESL Trust Services LLC bought a new stake in Pfizer during the 1st quarter worth about $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Down 0.2 %

Shares of PFE opened at $26.18 on Wednesday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The firm has a market cap of $148.36 billion, a P/E ratio of 35.38, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. The firm’s 50-day simple moving average is $28.84 and its 200 day simple moving average is $28.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.42%. Pfizer’s payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.